Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CINTO Trial
NCT07297069Phase 2Not yet recruiting
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Jan 2026
- Primary completion
- May 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab, tofacitinib oral solution in ulcerative colitis (UC), sponsored by Asian Institute of Gastroenterology. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
infliximabtofacitinib oral solution
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07297069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297069.